Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
Status:
COMPLETED
Trial end date:
2023-04-27
Target enrollment:
Participant gender:
Summary
The overall design of this clinical study is a single center, randomized, open label, single dose, two sequence, two cycle bioequivalence trial in healthy individuals under fasting conditions. According to the randomized crossover self-control method, healthy volunteer subjects were orally administered with Eltrombopag Olamine Tablets produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Evaluate the human bioequivalence of single dose Reference Listed Drug (RLD) after meals, providing reference for clinical evaluation and medication use.